Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

NEW YORK & MIAMI, July 10, 2018 — A Parkinson’s Foundation study recently published in the scientific journal, npj Parkinson’s Disease, reveals findings from the most comprehensive estimate of Parkinson’s disease in the United States and Canada to date. The Foundation’s “Parkinson’s Prevalence Project” estimates that 930,000 people in the United States will be living with the disease by 2020, further increasing to 1.2 million people by 2030.

parkinson's Prevalance Project infographic parkinson's Prevalance by State map"Our knowledge of Parkinson’s has evolved significantly and so should our understanding of the population that has this disease,” said James Beck, PhD, Parkinson’s Foundation Chief Scientific Officer and contributing author on the study. “These findings will help attract the attention of federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing Parkinson’s disease.”

The Parkinson’s Foundation formed the “Parkinson’s Prevalence Project” in 2014 to determine an updated estimate of the prevalence of Parkinson’s throughout North America. Prior estimates were deemed outdated and based on a small number of cases from small regional subpopulations – such as a study performed in a rural Mississippi county finding 26 cases was long used as the benchmark estimate for Parkinson’s prevalence in the US. The Parkinson’s Prevalence Project revised estimate draws from larger and more diverse populations and is almost double the previous estimate:

  • The research combined data from a multi-study sampling strategy in diverse geographic regions including California, Minnesota, Hawaii, and Ontario, Canada and compared those results to U.S. Medicare data.
  • The estimated overall prevalence of Parkinson’s among those 45 years old or older is 572 per 100,000, which translates into 680,000 individuals in the U.S. who are at least 45 years old with Parkinson’s in 2010, the date of the last official U.S. census.
  • The prevalence of Parkinson’s will rise to approximately 930,000 in 2020 and 1,238,000 in 2030 based on the U.S. Census Bureau population projections.

Connie Marras, MD, PhD, lead author on the study and movement disorder neurologist at the Movement Disorders Centre at Toronto Western Hospital, a Parkinson’s Foundation Center of Excellence and the Edmond J. Safra Program in Parkinson’s research said, “Like Alzheimer’s disease, Parkinson’s affects primarily older individuals and poses a significant health care burden, as well as a real challenge on how to care for the aging population over the coming decades.”

Added John L. Lehr, CEO of the Parkinson’s Foundation: “One million Americans living with Parkinson’s by 2020 highlights the growing importance of optimizing care and treatment for people with the disease today. We continue to support scientific research, including through our ‘Parkinson’s Outcomes Project,’ the largest clinical study of Parkinson’s in the world, to help better understand what causes the disease, how to treat it and potentially stop progression and improve the lives of everyone living with the disease.”

Later this year, the Parkinson’s Foundation will be leading phase two of the prevalence study to better understand, on a national scale, how many people are diagnosed each year with Parkinson’s as well as the rate of mortality of people with the disease.

For more information about Parkinson’s statistics, visit Parkinson.org/Statistics.

###

About the Parkinson’s Foundation 
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease 
Affecting nearly one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

 

Tuesday, July 10, 2018
Parkinson's Foundation Mourns the Loss of Robert Burke, MD
Friday, January 5, 2018

The Parkinson’s Foundation mourns the loss of Robert Burke, MD, professor of Neurology at Columbia University, a Parkinson’s Foundation Center of Excellence. He was a former member of the Parkinson’s Disease Foundation (PDF) Scientific Advisory Board and led the PDF Research Center at Columbia.

Parkinson's Foundation Study Finds Gender Disparities in Caregiving, with Women at a Disadvantage
Monday, December 4, 2017

Largest Clinical Study Tracking Parkinson’s Patients Over Time Shows Women with Parkinson’s Have Fewer Caregiving Resources than Men with Parkinson’s

Parkinson’s Foundation Invests $60,000 to Develop Innovative Models of Patient Engagement
Wednesday, November 29, 2017

Six Awards Foster Patient-Driven Parkinson’s Research

Jesse Jackson Diagnosed with Parkinson's Disease
Friday, November 17, 2017

Rev. Jesse Jackson’s announcement today that he has been living with Parkinson’s Disease since 2015 further proves that receiving a diagnosis of Parkinson's is not a death sentence. There are many ways that people living with Parkinson's can control the symptoms of the disease with exercise and physical therapy to help maintain mobility and balance.

Update on Tozadenant Trial for Parkinson’s
Thursday, November 16, 2017

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe..

Parkinson’s Foundation Adds Marcia Mondavi Borger to Board of Directors
Tuesday, November 14, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Marcia Mondavi Borger to its Board of Directors.

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger
Thursday, October 26, 2017

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

Parkinson’s Foundation Welcomes Two New Board Members
Tuesday, October 24, 2017

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

Parkinson's Foundation Unveils New Brand and Website
Thursday, October 19, 2017

NEW YORK and MIAMI /PRNewswire-USNewswire/ — The Parkinson's Foundation today announced the launch of its new brand and website following the recent merger of two legacy organizations – National Parkinson Foundation and Parkinson's Disease Foundation – as part of its mission to

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia
Friday, August 25, 2017

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.